Press Releases BioNTech SE

Equities

BNTX

US09075V1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
90.88 ^USD	-2.65%		+2.32%	-13.89%

May. 07	TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating	MT
May. 07	BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioNTech : First Quarter 2024 Financial Report	May. 06	PU
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update	May. 06	GL
Moderna Litigation Against BioNTech And Pfizer Stayed Pending IPR	May. 06	AQ
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech For Infringing MRNA Vaccine Patents	May. 03	AQ
BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Collaborations GmbH on the domination and profit and loss transfer agreement pursuant to Section 293a AktG	May. 02	PU
BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d)	May. 02	PU
BioNTech : Extracts from the minutes of the Annual General Meetings of 18 August 2017, 19 August 2019, 26 June 2020 and 22 June 2021 (2017/2019 share option program and 2021 share option program)	May. 02	PU
BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d)	May. 02	PU
BioNTech : Report of the Management Board on Agenda Item 13	May. 02	PU
BioNTech : Extracts from the minutes of the Annual General Meetings of 18 August 2017, 19 August 2019, 26 June 2020 and 22 June 2021 (2017/2019 share option program and 2021 share option program)	May. 02	PU
BioNTech : Draft of the domination and profit and loss transfer agreement between BioNTech SE and BioNTech Collaborations GmbH	May. 02	PU
BioNTech : Annual financial statements of BioNTech SE as of 31 December 2022	May. 02	PU
BioNTech : Annual Report 2022 with the Consolidated Financial Statements as of 31 December 2022, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2022 financial year	May. 02	PU
BioNTech : Annual financial statements of BioNTech SE as of 31 December 2023	May. 02	PU
BioNTech : Opening balance sheet of BioNTech Collaborations GmbH as of 18 March 2024	May. 02	PU
BioNTech : Registration and authorization form as well as authorization and instruction form	May. 02	PU
BioNTech : Invitation to the 2024 Annual General Meeting	May. 02	PU
BioNTech : Information pursuant to Section 125 AktG in conjunction with Article 4 (1) and Table 3 of Implementing Regulation (EU) 2018/1212	May. 02	PU
BioNTech : Annual Report 2023 with the Consolidated Financial Statements as of 31 December 2023, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2023 financial year	May. 02	PU
BioNTech : Annual Financial Statements as of 31 December 2023	May. 02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT